Lane, Heidi A <br/><br/>
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.  [electronic resource] 

 -  Seminars in oncology  Apr 2006 
 - S18-25 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>0093-7754 
<br/><br/><label>Standard No.: </label>10.1053/j.seminoncol.2006.03.024  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aromatase Inhibitors--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Clinical Trials as Topic<br/>Everolimus<br/>Female<br/>Forecasting<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Letrozole<br/>Neoplasms, Hormone-Dependent--drug therapy<br/>Nitriles--therapeutic use<br/>Receptors, Estrogen--metabolism<br/>Sirolimus--analogs & derivatives<br/>Triazoles--therapeutic use